Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05843292 | Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer(NeoSTEP) | not yet recruiting | Phase 4 | 48 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jun 6, 2023 | clinicaltrials |
| NCT02889458 | Hong Kong Breast Cancer Study | active not recruiting | — | 7,000 | The University of Hong KongOTHER | 1 | May 23, 2023 |
| clinicaltrials |
| NCT05447702 | Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | recruiting | Phase 2 | 35 | West China HospitalOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05834764 | Pyrotinib in Women With High-risk in Early Stage Breast Cancer | recruiting | Phase 2 | 188 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT02315196 | Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer | active not recruiting | Phase 2 | 62 | Rutgers, The State University of New JerseyOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05218044 | Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ(DCIS) | recruiting | N/A | 30 | Glendale Adventist Medical Center d/b/a Adventist Health GlendaleOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT04501523 | A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC(Apollo) | recruiting | Phase 2 | 460 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05698186 | Thero2-01S22 in HER2-positive Breast Cancer | not yet recruiting | Phase 3 | 320 | Institut de cancérologie Strasbourg EuropeOTHER | 0 | Jan 26, 2023 | clinicaltrials |
| NCT05627960 | First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies | recruiting | Phase 1 | 77 | A&G Pharmaceutical Inc.INDUSTRY | 1 | Nov 28, 2022 | clinicaltrials |
| NCT04985032 | Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT) | recruiting | — | 200 | RPCR, Inc.OTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT05388500 | Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)(PHARE-C) | not yet recruiting | Phase 3 | 800 | Institut de cancérologie Strasbourg EuropeOTHER | 0 | May 27, 2022 | clinicaltrials |
| NCT05037825 | The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors(PARADIGM) | recruiting | — | 800 | VastBiomeINDUSTRY | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05345860 | Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer(AMENDER) | recruiting | N/A | 300 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT04666961 | Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ(HORNEO01) | recruiting | Phase 2 | 262 | Institut Cancerologie de l'OuestOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT05067530 | Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study(CAREGIVER) | not yet recruiting | Phase 2 | 126 | Medical University of GdanskOTHER | 1 | Oct 5, 2021 | clinicaltrials |
| NCT04993014 | Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer(HER2Cell) | recruiting | Phase 2 | 80 | AC Camargo Cancer CenterOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT02603679 | Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases(PREDIX LumB) | active not recruiting | Phase 2 | 181 | Thomas HatschekOTHER | 1 | Aug 3, 2021 | clinicaltrials |
| NCT02568839 | Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer(PREDIX HER2) | active not recruiting | Phase 2 / Phase 3 | 202 | Thomas HatschekOTHER | 1 | Aug 13, 2020 | clinicaltrials |
| NCT04481763 | A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast | recruiting | Phase 1 / Phase 2 | 20 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jul 22, 2020 | clinicaltrials |
| NCT04481932 | Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer | recruiting | Phase 2 | 104 | Peking UniversityOTHER | 1 | Jul 22, 2020 | clinicaltrials |
| NCT02592083 | Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors(PREDIX LumA) | active not recruiting | Phase 2 | 10 | Thomas HatschekOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04437160 | Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy | recruiting | Phase 2 | 286 | Chinese Academy of Medical SciencesOTHER | 1 | Jun 18, 2020 | clinicaltrials |
| NCT04281641 | Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer(PHC-BC) | recruiting | N/A | 94 | Fudan UniversityOTHER | 1 | May 4, 2020 | clinicaltrials |
| NCT04301739 | to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC) | not yet recruiting | Phase 3 | 522 | Shanghai Henlius BiotechINDUSTRY | 0 | Mar 12, 2020 | clinicaltrials |
| NCT04225858 | Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy(ASICS) | not yet recruiting | N/A | 340 | The Netherlands Cancer InstituteOTHER | 0 | Jan 13, 2020 | clinicaltrials |
| NCT04158856 | Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer(SHERO) | not yet recruiting | Phase 2 | 60 | xuexin heOTHER | 0 | Nov 12, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Jun 6, 2023source: clinicaltrials